These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 27698552)

  • 21. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis.
    Correll CK; Bullock DR; Cafferty RM; Vehe RK
    Clin Rheumatol; 2018 Feb; 37(2):549-553. PubMed ID: 29103180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis.
    Liu SW; Velez NF; Lam C; Femia A; Granter SR; Townsend HB; Vleugels RA
    JAMA Dermatol; 2013 Oct; 149(10):1204-8. PubMed ID: 23986394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infliximab for juvenile idiopathic arthritis-associated uveitis.
    Richards JC; Tay-Kearney ML; Murray K; Manners P
    Clin Exp Ophthalmol; 2005 Oct; 33(5):461-8. PubMed ID: 16181269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients.
    Díaz-Llopis M; Salom D; Garcia-de-Vicuña C; Cordero-Coma M; Ortega G; Ortego N; Suarez-de-Figueroa M; Rio-Pardo MJ; Fernandez-Cid C; Fonollosa A; Blanco R; Garcia-Aparicio AM; Benitez-Del-Castillo JM; Olea JL; Arevalo JF
    Ophthalmology; 2012 Aug; 119(8):1575-81. PubMed ID: 22525047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial.
    Suhler EB; Lowder CY; Goldstein DA; Giles T; Lauer AK; Kurz PA; Pasadhika S; Lee ST; de Saint Sardos A; Butler NJ; Tessler HH; Smith JR; Rosenbaum JT
    Br J Ophthalmol; 2013 Apr; 97(4):481-6. PubMed ID: 23376607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adalimumab therapy for refractory childhood uveitis.
    Bravo-Ljubetic L; Peralta-Calvo J; Noval S; Pastora-Salvador N; Abelairas-Gómez J; Merino R
    J AAPOS; 2013 Oct; 17(5):456-9. PubMed ID: 24160962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of biologic therapies in uveitis.
    Duica I; Voinea LM; Mitulescu C; Istrate S; Coman IC; Ciuluvica R
    Rom J Ophthalmol; 2018; 62(2):105-113. PubMed ID: 30206553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry.
    Henderson LA; Zurakowski D; Angeles-Han ST; Lasky A; Rabinovich CE; Lo MS;
    Pediatr Rheumatol Online J; 2016 Feb; 14(1):9. PubMed ID: 26879972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple Sclerosis in a Patient with Intermediate Uveitis and Juvenile Idiopathic Arthritis Treated with Adalimumab: A Case Report.
    Rojas-Carabali W; Boada-Robayo L; Chacón-Zambrano D; Criollo Porras E; Kerguelén Dumar V; de-la-Torre A
    Ocul Immunol Inflamm; 2023 Nov; 31(9):1873-1876. PubMed ID: 36150118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.
    Foeldvari I; Becker I; Horneff G
    Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody.
    Baker DE
    Rev Gastroenterol Disord; 2004; 4(4):196-210. PubMed ID: 15580154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
    Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K
    Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TNF inhibition for ophthalmic indications: current status and outlook.
    Rifkin LM; Birnbaum AD; Goldstein DA
    BioDrugs; 2013 Aug; 27(4):347-57. PubMed ID: 23568177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-tumor necrosis factor-α therapy in uveitis.
    Cordero-Coma M; Sobrin L
    Surv Ophthalmol; 2015; 60(6):575-89. PubMed ID: 26164735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advancements in the management of uveitis.
    Schwartzman S
    Best Pract Res Clin Rheumatol; 2016 Apr; 30(2):304-315. PubMed ID: 27886802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis.
    Lerman MA; Rabinovich CE
    Paediatr Drugs; 2015 Aug; 17(4):283-301. PubMed ID: 25893479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting.
    Tarkiainen M; Tynjälä P; Vähäsalo P; Lahdenne P
    Rheumatology (Oxford); 2015 Jul; 54(7):1170-6. PubMed ID: 25504896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.
    Thomas AS
    Curr Opin Ophthalmol; 2019 May; 30(3):138-150. PubMed ID: 30844945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uveitis Reactivation in Children Treated With Tumor Necrosis Factor Alpha Inhibitors.
    Lerman MA; Lewen MD; Kempen JH; Mills MD
    Am J Ophthalmol; 2015 Jul; 160(1):193-200.e1. PubMed ID: 25892124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis.
    Rusche H; Marrani E; Real-Fernandez F; Ponti R; Terzani F; Maccora I; Monasson O; Mastrolia MV; Peroni E; Pagnini I; Cimaz R; Papini AM; Simonini G; Rovero P
    Sci Rep; 2021 Aug; 11(1):16393. PubMed ID: 34385564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.